Molecular-Guided Off-Label Targeted Therapy in a Large-Scale Precision Oncology Program.

Vishal Vashistha Evangelia KatsoulakisAixia GuoMeghan J PriceSara AhmedMichael J Kelley

Published in: JCO precision oncology (2023)

Although administration of off-label TAs is infrequent after CGP, more than one quarter of treatment regimens led to response. TAs associated with level 4 annotations lead to worse outcomes than TAs bearing higher levels of evidence.

Keyphrases

palliative care
type diabetes
metabolic syndrome
adipose tissue
single molecule
light emitting